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Problem: high dose oxycodone and XR
hydromorphone pose serious abuse potential
and safety risk


VT has passed new legislation rules regulating prescribing practices to
minimize the risk of opioid abuse in our communities. “This rule
provides legal requirements for the appropriate use of opioids in
treating chronic pain in order to minimize opportunities for misuse,
abuse, and diversion, and optimize prevention of addiction and
overdose.”



Long term use of opiate medication for pain leads to tolerance,
addiction, abuse, diversion, and adverse effects



There is dose dependent evidence of increased risk of overdose, abuse
and dependence, fracture, and myocardial infarction



Prescribers are responsible for release of these drugs into
communities but need to be aware of best practices to ensure safety
to themselves, their patients, and their communities

Cost considerations



Nationally, of the 22,767 deaths relating to
prescription drug overdose in 2013, 16,235
(71.3%) involved opioid painkillers.
Prescription opioid abuse costs were about
$55.7 billion in 2007



Vermont’s overdose death rate for 2010 is
9.7 per 100,000 population, about 60
deaths/year



Street value of oxycodone and hydrocodone
are somewhere between $1-2 per milligram
in VT. Therefore, a 30mg daily script has a
$60 daily or $1680 monthly value. This
represents incentive for diversion.

Prescription costs
Tablets (Oxycodone-Acetaminophen)
2.5-325 mg (100): $204.91
5-325 mg (100): $136.87
7.5-325 mg (100): $271.54
10-325 mg (100): $355.08
Tablets (Percocet)
2.5-325 mg (100): $743.50
5-325 mg (100): $1040.57
7.5-325 mg (100): $1124.22
10-325 mg (100): $1470.01
Tablets (OxyCODONE HCl)
5 mg (100): $54.11
10 mg (100): $62.50
15 mg (100): $189.48
20 mg (100): $110.30
30 mg (100): $358.93

Morrisville Community Cost and Perspectives


There are 29 patients in the Morrisville Family Health Care
practice being treated with chronic high dose opiates that are
not abuse resistant, accounting for thousands of Percocet and
Oxycodone pills released into the town and greater community
(Morrisville, Hyde Park, Eden, Elmore, Hardwick, Stowe and
more) per month. This represents a street value of $30,000$50,000 per month and may contribute to adverse health effects
and overdose in the community. As a principle source of
prescription opioids for the region, this practice must be
responsible and accountable for its prescription practices.
Interviews with several providers (Kim Bruno, Dave Roy, Phil
Kiely) and a community coordinator (Jean Audet) provided
feedback about various aspects of prescription narcotics in the
region.

Community perspectives: Prescriber Interviews






What is your strategy, pharmacological and otherwise, for managing chronic pain?


Kim Bruno: “I make sure to go through lots of modalities like PT, exercise, mental health management,
antidepressants, neuromodulators, lidocaine patches, before chronic [opioid] pain meds. Its not perfect because
not everyone [patients] is willing to do it”



Dave Roy: “I go through the litany of pain medications, clinics, epidurals. I find clinics are typically useless for
med management help. Chronic pain groups can help, but I haven’t seen a lot of success with that kind of stuff.”

Do the prescribing habits of providers in the practice put the community at risk?


KB: “We put the community at risk. Some of us prescribe more than others, some are less stern than others. Loosy
goosy habits put the community at risk. We are good about not just blindly refilling and we make patients
understand their responsibility. If you don’t believe in chronic pain you wont see it because patients will leave
you. Fundamentally it is a risk we need to take.”



DR: “Anyone who prescribes is at risk of causing harm. Don’t believe the patients every time ‘the dog ate the
pill’. Some people may be pulling the wool over my eyes. The tradeoff is not giving meds to people that really
need it, which is as bad if not worse. I have been more aggressively monitoring in that last year and have caught a
few people with random urine screens. VPMS has not helped me to bust anybody.”

What do you if a narcotics contract is breached?


KB: “I have had few breaches and I stopped prescribing. Im not afraid to kick them out. For a couple of patients I
switched to long acting formulations, increased frequency of visits, shortened script duration, pill counts and
urines”



DR: “it depends on what happens. I don’t lose a lot of sleep if its positive for marijuana. If I catch something in a
urine I will confront patients and have had to discontinue patients in the past. I will confirm on dominion. If I
catch overt diversion I throw them out of practice. But if it’s a legitimate mistake I try to help.”

Interviews continued




What is your understanding of the research regarding the efficacy of long
term pain management with narcotics?


KB: “Its not great research. This approach is not based in great science. These meds
perpetuate pain rather than treat it over time.”



DR: “I know that there is evidence that its not that beneficial. I think regardless of
research there is a subgroup of patients that this medicine just seems to work for. I
am more judicious about starting patients and increasing dosage now than I used to
be.”

How would you feel about using a new standardized template for pain
management documentation?


KB: “I would be all over it”



DR: “I would have to look at it kind of closely and see. It’s a good way to make sure
everything is covered but it makes it difficult to think outside the box. I look at
anything that is rigid as iffy.”

Intervention: form a database of at risk
patients and assess documentation
compliance with VT rules


Methodology


Practice list obtained of all patients prescribed long term narcotics
without anti-abuse formulations



Patients taking high dose (>30 mg oxycodone or >40mg XR
hydromorphone) identified from larger group



Records of each patient were audited for compatibility with new
VT guidelines for effective monitoring and documentation



Database created to capture documentation metrics



Data analyzed to determine rates of compliance with guidelines



Evaluation and recommendations for the future made to practice

Results
Overall
compliance: 65%
Range: 33-92%

Compliance with Rule Governing the Prescribing of Opioids for Chronic Pain

Documentation requirements prior to initiating prescription
Medical and physical evaluation
Diagnoses supporting use of medication
Risks and benefits of medication
Inability to control pain with alternative therapies
Informed consent

Controlled substance treatment agreement
VPMS query documentation
Review of prior controlled substance prescriptions
Repeat query every 120 days
Prescription requirements
Presciption has maximum daily dose
Prescription is for a 30 day maximum
Follow up visit documentation requirements
Whether to continue prescribing
Need for substance abuse consultaltion
Provider explanation and patient agreement of consequences of
agreement violation
Follow up visit every 180 days

Percentage Compliant
90%
97%
Incomplete data
Incomplete data
79%

93%
Incomplete data
Has not yet started
100%
100%
86%
0%
7%
93%

Evaluation






Physicians are performing well in the following areas:


writing prescriptions with maximum dosage for a maximum of 30 days (100%)



Documentation of diagnosis (97%)



routine follow up visits (93%)



Controlled substance agreement documentation (93%)

Physicians need improvement in the following areas of documentation:


Informed consent (79%)



Explanation of consequences of failure to adhere to contract (7%)



Whether there is need for substance abuse counselling (0%)

Limitations


Data for patients who have been on these medications since before EMR records
were in use or were initiated by physicians from other practices was often
incomplete



It is difficult to measure the effect of prescribing practices and drug abuse with a
small sample size in a small community



According to interviews, physicians have different opinions about whether a
standardized template would be acceptable within their practices

Future recommendations
1) A chronic opioid for pain management template should be developed that is used for each initial
patient visit. This should include:


Diagnosis requiring pain management with high dose opioid: _________



Risks and benefits of medication discussed? Yes/No



Non opioid treatment options are ineffective, not tolerated, or inadequate? Yes/No

2) A chronic opioid for pain management template should be developed that is used for each follow up
visit. This should include:


Continuation of high dose opioid prescription? Yes/No



Patient was made aware of consequences of failure to adhere to controlled substance agreement? Yes/No



Substance abuse services recommended? Yes/No

3) An EHR alert should be created to notify physicians when a patient that is missing an informed
consent or narcotics contract comes in for an office visit
4) This audit should be repeated in 1 year to measure improvement in documentation
Improvement in the documentation process will remind physicians to address important issues that
they may not be talking about now. Because this patient population is at high risk for medication
abuse and adverse effects, safety will be improved by making these improvements. Furthermore, the
community at large will be safer because responsible medication use is more likely to prevent
diversion.
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